Blockade of MMP14 activity in murine breast carcinomas: Implications for macrophages, vessels, and radiotherapy

Journal of the National Cancer Institute

Volumn 107, Issue 4, 2015, Pages

  Ager, Eleanor I ^a,b,c   Kozin, Sergey V ^a   Kirkpatrick, Nathaniel D ^a,d   Seano, Giorgio ^a,e   Kodack, David P ^a   Askoxylakis, Vasileios ^a   Huang, Yuhui ^a   Goel, Shom ^a,h   Snuderl, Matija ^a,f   Muzikansky, Alona ^a   Finkelstein, Dianne M ^a   Dransfield, Daniel T ^g,i   Devy, Laetitia ^g,j   Boucher, Yves ^a   Fukumura, Dai ^a   Jain, Rakesh K ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c Novogen Ltd   (Australia)

^d NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^e UNIVERSITY OF SYDNEY   (Australia)

^f NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g Dyax Corp   (United States)

^h HARVARD MEDICAL SCHOOL   (United States)

ⁱ Harvard Medical School ^*  (United States)

^j MERCK SERONO S A   (Switzerland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DX 2400; IMMUNOGLOBULIN G; INDUCIBLE NITRIC OXIDE SYNTHASE; MATRIX METALLOPROTEINASE 14; MATRIX METALLOPROTEINASE INHIBITOR; NITRIC OXIDE SYNTHASE INHIBITOR; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; AMIDINE; BENZYLAMINE DERIVATIVE; ENZYME INHIBITOR; MMP14 PROTEIN, HUMAN; MONOCLONAL ANTIBODY; N-(3-(AMINOMETHYL)BENZYL)ACETAMIDINE; NOS2 PROTEIN, HUMAN; SMAD2 PROTEIN; SMAD2 PROTEIN, HUMAN; SMAD3 PROTEIN; SMAD3 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CARCINOMA; CANCER RADIOTHERAPY; ENZYME INHIBITION; GROWTH; MACROPHAGE; MOUSE; NONHUMAN; PERFUSION; PHENOTYPE; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR GROWTH; TUMOR VASCULARIZATION; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; BREAST NEOPLASMS; DRUG EFFECTS; ENZYMOLOGY; EXPERIMENTAL MAMMARY NEOPLASM; FEMALE; GENE EXPRESSION REGULATION; HUMAN; IMMUNOLOGY; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); RADIATION DOSE FRACTIONATION; SIGNAL TRANSDUCTION; TUMOR CELL LINE; UPREGULATION; VASCULARIZATION;

AMIDINES; ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BENZYLAMINES; BREAST NEOPLASMS; CELL LINE, TUMOR; DOSE FRACTIONATION; ENZYME INHIBITORS; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOGLOBULIN G; MACROPHAGES; MAMMARY NEOPLASMS, EXPERIMENTAL; MATRIX METALLOPROTEINASE 14; MICE; NEOVASCULARIZATION, PATHOLOGIC; NITRIC OXIDE SYNTHASE TYPE II; PHENOTYPE; SIGNAL TRANSDUCTION; SMAD2 PROTEIN; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; UP-REGULATION;

EID: 84930713865     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djv017     Document Type: Article

References (47)

1. Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell. 2010;141(1):52-67.
2. Tetu B, Brisson J, Wang CS, et al. The influence of MMP-14, TIMP-2 and MMP-2 expression on breast cancer prognosis. Breast Cancer Res. 2006;8(3):R28.
3. Jiang WG, Davies G, Martin TA, et al. Expression of membrane type-1 matrix metalloproteinase, MT1-MMP in human breast cancer and its impact on invasiveness of breast cancer cells. Int J Mol Med. 2006;17(4):583-590.
4. Coussens LM, Fingleton B, Matrisian LM. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science. 2002;295(5564):2387-2392.
5. Pavlaki M, Zucker S. Matrix metalloproteinase inhibitors (MMPIs): the beginning of phase I or the termination of phase III clinical trials. Cancer Metastasis Rev. 2003;22(2-3):177-203.
6. Glasspool RM, Twelves CJ. Matrix metalloproteinase inhibitors: past lessons and future prospects in breast cancer. Breast. 2001;10(5):368-378.
7. Hidalgo M, Eckhardt SG. Development of matrix metalloproteinase inhibitors in cancer therapy. J Natl Cancer Inst. 2001;93(3):178-193.
8. Perentes JY, Kirkpatrick ND, Nagano S, et al. Cancer Cell-Associated MT1-MMP Promotes Blood Vessel Invasion and Distant Metastasis in Triple-Negative Mammary Tumors. Cancer Res. 2011;71(13):4527-4538.
9. Devy L, Huang L, Naa L, et al. Selective inhibition of matrix metalloproteinase-14 blocks tumor growth, invasion, and angiogenesis. Cancer Res. 2009;69(4):1517-1526.
10. Kaimal R, Aljumaily R, Tressel SL, et al. Selective blockade of matrix metalloprotease-14 with a monoclonal antibody abrogates invasion, angiogenesis and tumor growth in ovarian cancer. Cancer Res. 2013;73(8):2457-2467.
11. Alfranca A, Lopez-Oliva JM, Genis L, et al. PGE2 induces angiogenesis via MT1-MMP-mediated activation of the TGFbeta/Alk5 signaling pathway. Blood. 2008;112(4):1120-1128.
12. Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature. 2011;473(7347):298-307.
13. Cheng G, Liao S, Kit Wong H, et al. Engineered blood vessel networks connect to host vasculature via wrapping-and-tapping anastomosis. Blood. 2011;118(17):4740-4749.
14. Goel S, Duda DG, Xu L, et al. Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev. 2011;91(3):1071-1121.
15. Carmeliet P, Jain RK. Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat Rev Drug Discov. 2011;10(6):417-427.
16. Winkler F, Kozin SV, Tong RT, et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell. 2004;6(6):553-563.
17. Richardsen E, Uglehus RD, Johnsen SH, Busund LT. Immunohistochemical expression of epithelial and stromal immunomodulatory signalling molecules is a prognostic indicator in breast cancer. BMC Res Notes. 2012;5:110.
18. Sounni NE, Dehne K, van Kempen L, et al. Stromal regulation of vessel stability by MMP14 and TGFbeta. Dis Model Mech. 2010;3(5-6):317-332.
19. van Meeteren LA, Goumans MJ, ten Dijke P. TGF-beta receptor signaling pathways in angiogenesis;emerging targets for anti-angiogenesis therapy. Curr Pharm Biotechnol. 2011;12(12):2108-2120.
20. Liu J, Liao S, Diop-Frimpong B, et al. TGF-beta blockade improves the distribution and efficacy of therapeutics in breast carcinoma by normalizing the tumor stroma. Proc Natl Acad Sci U S A. 2012;109(41):16618-16623.
21. Fridlender ZG, Sun J, Kim S, et al. Polarization of tumor-associated neutrophil phenotype by TGF-beta: "N1"versus "N2"TAN. Cancer Cell. 2009;16(3):183-194.
22. Krstic J, Santibanez JF. Transforming growth factor-beta and matrix metalloproteinases: functional interactions in tumor stroma-infiltrating myeloid cells. Scientific World J. 2014;2014:521754.
23. Luo H, Hao Y, Tang B, Zeng D, Shi Y, Yu P. Mouse forestomach carcinoma cells immunosuppress macrophages through transforming growth factor-beta1. Mol Med Rep. 2012;5(4):988-992.
24. Wu A, Wei J, Kong LY, et al. Glioma cancer stem cells induce immunosuppressive macrophages/microglia. Neuro Oncol. 2010;12(11):1113-1125.
25. Wrzesinski SH, Wan YY, Flavell RA. Transforming growth factor-beta and the immune response: implications for anticancer therapy. Clin Cancer Res. 2007;13(18 Pt 1):5262-5270.
26. Wojtowicz-Praga S. Reversal of tumor-induced immunosuppression by TGFbeta inhibitors. Invest New Drugs. 2003;21(1):21-32.
27. Hao NB, Lu MH, Fan YH, Cao YL, Zhang ZR, Yang SM. Macrophages in tumor microenvironments and the progression of tumors. Clin Dev Immunol. 2012;2012:948098.
28. Vakoc BJ, Lanning RM, Tyrrell JA, et al. Three-dimensional microscopy of the tumor microenvironment in vivo using optical frequency domain imaging. Nat Med. 2009;15(10):1219-1223.
29. Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis. Nat Methods. 2012;9(7):671-675.
30. Nagareddy PR, Rajput PS, Vasudevan H, et al. Inhibition of matrix metalloproteinase-2 improves endothelial function and prevents hypertension in insulin-resistant rats. Br J Pharmacol. 2012;165(3):705-715.
31. Butler GS, Dean RA, Tam EM, Overall CM. Pharmacoproteomics of a metalloproteinase hydroxamate inhibitor in breast cancer cells: dynamics of membrane type 1 matrix metalloproteinase-mediated membrane protein shedding. Mol Cell Biol. 2008;28(15):4896-4914.
32. Luo S, Wang T, Qin H, Lei H, Xia Y. Obligatory role of heat shock protein 90 in iNOS induction. Am J Physiol Cell Physiol. 2011;301(1):C227-C233.
33. Perfetto B, Buommino E, Canozo N, et al. Interferon-gamma cooperates with Helicobacter pylori to induce iNOS-related apoptosis in AGS gastric adenocarcinoma cells. Res Microbiol. 2004;155(4):259-266.
34. Garban HJ, Bonavida B. Nitric oxide sensitizes ovarian tumor cells to Fasinduced apoptosis. Gynecol Oncol. 1999;73(2):257-264.
35. Berra A, Ganzinelli S, Saravia M, Borda E, Sterin-Borda L. Inducible nitric oxide synthase subserves cholinergic vasodilation in retina. Vis Neurosci. 2005;22(3):371-377.
36. Bustamante SA, Pang Y, Romero S, et al. Inducible nitric oxide synthase and the regulation of central vessel caliber in the fetal rat. Circulation. 1996;94(8):1948-1953.
37. Huang Y, Stylianopoulos T, Duda DG, Fukumura D, Jain RK. Benefits of vascular normalization are dose and time dependent-letter. Cancer Res. 2013;73(23):7144-7146.
38. Fukumura D, Kashiwagi S, Jain RK. The role of nitric oxide in tumour progression. Nat Rev Cancer. 2006;6(7):521-534.
39. Rai RK, Vishvakarma NK, Mohapatra TM, Singh SM. Augmented macrophage differentiation and polarization of tumor-associated macrophages towards M1 subtype in listeria-administered tumor-bearing host. J Immunother. 2012;35(7):544-554.
40. Mamessier E, Sylvain A, Thibult ML, et al. Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity. J Clin Invest. 2011;121(9):3609-3622.
41. Ascierto ML, Idowu MO, Zhao Y, et al. Molecular signatures mostly associated with NK cells are predictive of relapse free survival in breast cancer patients. J Transl Med. 2013;11(1):145.
42. Bruno A, Focaccetti C, Pagani A, et al. The proangiogenic phenotype of natural killer cells in patients with non-small cell lung cancer. Neoplasia. 2013;15(2):133-142.
43. Stylianopoulos T, Martin JD, Chauhan VP, et al. Causes, consequences, and remedies for growth-induced solid stress in murine and human tumors. Proc Natl Acad Sci U S A. 2012;109(38):15101-15108.
44. Stylianopoulos T, Jain RK. Combining two strategies to improve perfusion and drug delivery in solid tumors. Proc Natl Acad Sci U S A. 2013;110(46):18632-18637.
45. Chauhan VP, Martin JD, Liu H, et al. Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels. Nat Commun. 2013;4:2516.
46. Jiang H, De Ridder M, Verovski VN, et al. Activated macrophages as a novel determinant of tumor cell radioresponse: the role of nitric oxide-mediated inhibition of cellular respiration and oxygen sparing. Int J Radiat Oncol Biol Phys. 2010;76(5):1520-1527.
47. Bouquet F, Pal A, Pilones KA, et al. TGFbeta1 inhibition increases the radiosensitivity of breast cancer cells in vitro and promotes tumor control by radiation in vivo. Clin Cancer Res. 2011;17(21):6754-6765.